SYHX-2011

SYHX-2011 is an investigational small molecule antineoplastic drug developed by CSPC Ouyi Pharmaceutical for the treatment of advanced and metastatic breast cancer. It is a novel nano-preparation based on paclitaxel (albumin-bound type), designed to improve efficacy, safety, and compatibility compared to existing therapies. The drug is administered intravenously and has independent intellectual property rights. Its primary indication is for patients with metastatic breast cancer who have failed combination chemotherapy or experienced recurrence within six months after adjuvant chemotherapy. The precise mechanism of action remains undefined, but it builds upon the established cytotoxic effects of taxanes in breast cancer therapy[1][2][5][7].

Other names

syhx2011syhx-2011syhx 2011